News

Breadcrumb

Home
News

All News

SPR raises $5 million Series A

Company news

Pagination

Previous page
Page1
Page2
Page3
Current page4

Healthcare Professionals
Patients & Caregivers
- SPRINT® PNS System
- Resources
About Us
News
Events
Careers
- Overview
- Job Listing
Contact Us

CPRA Requests
Consumer Health Data Request Form
Compliance
FCOI Policy
MRI Safety Information
Patent Information
Product Terms and Conditions
Safety Information
Trademarks
Billing Portal

Consumer Health Data and Information Privacy Policy
Terms of Use

Visit us on Facebook

Visit us on Twitter

Visit us on Instagram

Visit us on YouTube

Visit us on LinkedIn

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View references for support of all claims.

Product and brand names/logos are registered or common law trademarks of SPR.